Fintel reports that on April 14, 2023,
Morgan Stanley
maintained
coverage of Viewray (NASDAQ:VRAY) with
a Equal-Weight recommendation.
Analyst Price Forecast Suggests 459.04% Upside
As of April 6, 2023,
the average one-year price target for Viewray is $7.27.
The forecasts range from a low of $5.56 to a high of $8.40.
The average price target represents an increase of 459.04% from its latest reported closing price of $1.30.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Viewray
is $139MM, an increase of 36.47%.
The projected annual non-GAAP EPS
is -$0.57.
What are Other Shareholders Doing?
Invesco
holds 64K shares
representing 0.04% ownership of the company.
In it’s prior filing, the firm reported owning 65K shares, representing
a decrease
of 0.81%.
The firm
decreased
its portfolio allocation in VRAY by 99.99% over the last quarter.
Quantbot Technologies
holds 2K shares
representing 0.00% ownership of the company.
In it’s prior filing, the firm reported owning 0K shares, representing
an increase
of 100.00%.
Tudor Investment Corp Et Al
holds 418K shares
representing 0.23% ownership of the company.
In it’s prior filing, the firm reported owning 452K shares, representing
a decrease
of 8.16%.
The firm
increased
its portfolio allocation in VRAY by 4.26% over the last quarter.
JOHN HANCOCK VARIABLE INSURANCE TRUST – Strategic Equity Allocation Trust Series NAV
holds 24K shares
representing 0.01% ownership of the company.
In it’s prior filing, the firm reported owning 25K shares, representing
a decrease
of 4.01%.
The firm
increased
its portfolio allocation in VRAY by 11.59% over the last quarter.
VBINX – Vanguard Balanced Index Fund Investor Shares
holds 134K shares
representing 0.07% ownership of the company.
No change in the last quarter.
What is the Fund Sentiment?
There are 341 funds or institutions reporting positions in Viewray.
This is an increase
of
20
owner(s) or 6.23% in the last quarter.
Average portfolio weight of all funds dedicated to VRAY is 0.18%,
a decrease
of 33.95%.
Total shares owned by institutions decreased
in the last three months by 7.38% to 167,741K shares.
The put/call ratio of VRAY is 1.41, indicating a
bearish
outlook.
ViewRay Background Information
(This description is provided by the company.)
ViewRay, Inc., designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian’s high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
See all Viewray regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
